Results 81 to 90 of about 13,127 (167)

Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir

Journal of Microbiology, Immunology and Infection, 2018
Background: T-705 (favipiravir) is a potent inhibitor of RNA-dependent RNA polymerases of influenza viruses and no favipiravir-resistant virus has been isolated.
Tohru Daikoku, Mineyuki Mizuguchi, Takayuki Obita, Takeshi Yokoyama, Yoshihiro Yoshida, Masaya Takemoto, Kimiyasu Shiraki   +6 more
doaj   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease

Viruses
Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013 ...
Dylan M. Johnson, Terry Juelich, Lihong Zhang, Jennifer K. Smith, Birte K. Kalveram, David Perez, Jeanon Smith, Michael R. Grimes, Tania Garron, Maricela Torres, Shane Massey, Trevor Brasel, David W. C. Beasley, Alex N. Freiberg, Jason E. Comer   +14 more
doaj   +1 more source

Chitosan–Alginate Polyelectrolyte Systems: From Classical Release Models to the D‐PARMO Framework

Macromolecular Materials and Engineering, Volume 311, Issue 5, May 2026.
Classical empirical models fail to predict the dynamic in vivo behavior of chitosan‐alginate nanocarriers. Bridging this translational gap, the novel D‐PARMO framework replaces purely descriptive curve‐fitting with a mechanistically informed operational model.
Parastoo Rekab, Akeem Adeyemi Oladipo
wiley   +1 more source

Intranasal favipiravir in experimental rabies infection due to different variants

, 2023
A raiva é uma doença zoonótica, altamente letal, transmitida por mamíferos, com rápida progressão viral e evolução clínica, sem protocolo terapêutico eficaz até o momento, o que incita a busca de um antiviral mais eficiente.
Ribeiro, Bruna Letícia Devidé
core  

Determining the mutation bias of favipiravir in influenza using next-generation sequencing

, 2018
Favipiravir is a broad-spectrum antiviral drug that may be used to treat influenza. Previous research has identified that favipiravir likely acts as a mutagen but the precise mutation bias that favipiravir induces in influenza virus RNAs has not been ...
Lackenby, Angie, Barclay, Wendy, Galiano, Monica, Kellam, Paul, Zambon, Maria, Xie, Hongyao, Goldhill, Daniel H, Langat, Pinky, Miah, Shahjahan   +8 more
core   +1 more source

Investigation of Antimicrobial, Cytotoxic, and Larvicidal Activities of Favipiravir

, 2023
Growing number of deaths due to decreased effects of antibiotics has increased the need for new antimicrobial drugs. Studies on the pharmacological effect and toxicity of favipiravir, a new antiviral drug that was informally recommended by World Health ...
Aksakal, Abdulbaki, Uslu, Ugur, Lolak, Nebih, Aydin, Hasan, Sait, Ahmet, Korkmaz, Serol, Akocak, Suleyman   +6 more
core   +1 more source

Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)

Pneumonia
Purpose To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia. Methods A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID ...
Juan P. Horcajada, Rebeca Aldonza, Mónica Real, Silvia Castañeda-Espinosa, Elena Sendra, Joan Gomez-Junyent, Inmaculada López-Montesinos, Silvia Gómez-Zorrilla, Silvia Briansó, Montserrat Duran-Taberna, Andrés Fernández, Cristina Tarragó, Teresa Auguet-Quintillá, the COVID-MAR Research group, the COVID-HJ23 group   +14 more
doaj   +1 more source

Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)

Разработка и регистрация лекарственных средств
Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses antiviral properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2).
T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, A. V. Taganov, I. E. Shohin   +9 more
doaj   +1 more source

Role of favipiravir in the treatment of COVID-19

, 2020
The COVID-19 outbreak all over the world has led the researchers to strive for developing drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated.
Barkate, Hanmant, Parkar, Jalil, Ansari, Abdul, Tiwaskar, Mangesh, Joshi, Shashank, Talwar, Deepak, Vora, Agam, Patil, Saiprasad   +7 more
core   +1 more source